JP2020527559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527559A5 JP2020527559A5 JP2020501505A JP2020501505A JP2020527559A5 JP 2020527559 A5 JP2020527559 A5 JP 2020527559A5 JP 2020501505 A JP2020501505 A JP 2020501505A JP 2020501505 A JP2020501505 A JP 2020501505A JP 2020527559 A5 JP2020527559 A5 JP 2020527559A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023062212A JP2023106366A (ja) | 2017-07-12 | 2023-04-06 | タウタンパク質分解の化合物 |
| JP2024209477A JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531773P | 2017-07-12 | 2017-07-12 | |
| US62/531,773 | 2017-07-12 | ||
| PCT/US2018/041787 WO2019014429A1 (en) | 2017-07-12 | 2018-07-12 | COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062212A Division JP2023106366A (ja) | 2017-07-12 | 2023-04-06 | タウタンパク質分解の化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527559A JP2020527559A (ja) | 2020-09-10 |
| JP2020527559A5 true JP2020527559A5 (https=) | 2021-08-19 |
| JP7260521B2 JP7260521B2 (ja) | 2023-04-18 |
Family
ID=65001509
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501505A Active JP7260521B2 (ja) | 2017-07-12 | 2018-07-12 | タウタンパク質分解の化合物 |
| JP2023062212A Withdrawn JP2023106366A (ja) | 2017-07-12 | 2023-04-06 | タウタンパク質分解の化合物 |
| JP2024209477A Pending JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023062212A Withdrawn JP2023106366A (ja) | 2017-07-12 | 2023-04-06 | タウタンパク質分解の化合物 |
| JP2024209477A Pending JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210154184A1 (https=) |
| EP (2) | EP3652329B1 (https=) |
| JP (3) | JP7260521B2 (https=) |
| AU (1) | AU2018300982B2 (https=) |
| CA (1) | CA3069181A1 (https=) |
| ES (1) | ES2965049T3 (https=) |
| WO (1) | WO2019014429A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2767532T3 (en) | 2012-12-21 | 2016-09-12 | Nat Inst For Quantum And Radiological Science And Tech | New connection for reproduction of tau protein heavy in the brain. |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| MX2019005007A (es) * | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| ES2965049T3 (es) * | 2017-07-12 | 2024-04-10 | Dana Farber Cancer Inst Inc | Compuestos para la degradación de la proteína tau |
| PT3728207T (pt) | 2017-12-21 | 2023-03-14 | Ribon Therapeutics Inc | Quinazolinonas como inibidores de parp14 |
| CN111936498B (zh) | 2018-03-26 | 2024-04-16 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| IL302595A (en) * | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
| FI3784663T3 (fi) | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi |
| TW201946624A (zh) | 2018-05-09 | 2019-12-16 | 新旭生技股份有限公司 | 雜芳基化合物及其用途 |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| US11389438B2 (en) * | 2019-02-25 | 2022-07-19 | Chdi Foundation, Inc. | Compounds for targeting mutant huntingtin protein and uses thereof |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| CA3142002A1 (en) * | 2019-06-19 | 2020-12-24 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
| EP3999182A1 (en) * | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| CN114521196A (zh) * | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| CN114728071B (zh) * | 2019-11-13 | 2024-12-06 | 新旭生技股份有限公司 | 用于降解tau蛋白聚集体的化合物及其用途 |
| CN110878095B (zh) * | 2019-12-02 | 2023-01-24 | 中山大学 | 一种姜黄素双功能分子及其制备方法和应用 |
| EP4121046A4 (en) * | 2020-03-18 | 2024-04-24 | Dana-Farber Cancer Institute, Inc. | Targeted degraders of aberrant tau based on the pet tracer pbb3 |
| EP4138921A1 (en) * | 2020-04-23 | 2023-03-01 | University Of Iowa Research Foundation | Gper proteolytic targeting chimeras |
| CA3183431A1 (en) * | 2020-05-15 | 2021-11-18 | Vib Vzw | Means and methods for the treatment of pathological aggregation |
| KR20230018431A (ko) * | 2020-05-28 | 2023-02-07 | 브리스톨-마이어스 스큅 컴퍼니 | 갈렉틴-3 억제제 |
| AU2021293907A1 (en) * | 2020-06-17 | 2023-01-19 | Dana-Farber Cancer Institute, Inc. | Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system |
| WO2022201063A1 (en) * | 2021-03-23 | 2022-09-29 | Covabind Joint Research Private Limited | Nanoparticle composition for targeted protein degradation |
| EP4337259A1 (en) | 2021-05-14 | 2024-03-20 | Aprinoia Therapeutics Limited | Compounds for degrading alpha-synuclein aggregates and uses thereof |
| EP4351574B1 (en) | 2021-06-07 | 2026-03-04 | The General Hospital Corporation | Inhibitors of ttbk1 |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| EP4147723A1 (en) | 2021-09-09 | 2023-03-15 | Booster Therapeutics GmbH | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods) |
| EP4398941A1 (en) * | 2021-09-09 | 2024-07-17 | Booster Therapeutics GmbH | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods) |
| WO2024081690A2 (en) * | 2022-10-11 | 2024-04-18 | The General Hospital Corporation | Engineered bifunctional receptors and uses thereof |
| WO2024182633A2 (en) * | 2023-03-01 | 2024-09-06 | The Regents Of The University Of California | Targeted dephosphorylation of tau |
| CN116344058B (zh) * | 2023-05-29 | 2023-08-18 | 之江实验室 | 一种基于图信号的阿尔兹海默风险标注方法及装置 |
| WO2025117551A1 (en) * | 2023-11-27 | 2025-06-05 | Amydis, Inc. | Amino acid derivatives for detecting neurological disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8932557B2 (en) * | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| US9378662B2 (en) | 2011-08-04 | 2016-06-28 | Ats Holdings Llc | Simplified spine testing device |
| TW201605852A (zh) * | 2013-09-26 | 2016-02-16 | 美國禮來大藥廠 | 新穎化合物及其製備ｔａｕ造影劑及ｔａｕ造影調配物之用途 |
| CA2920068A1 (en) * | 2013-09-26 | 2015-04-02 | F. Hoffmann-La Roche Ag | Imidazo[1,2-a]pyridin-7-amines as imaging tools |
| EP3061748A4 (en) | 2013-10-22 | 2017-04-05 | Clino Ltd. | Tau imaging probe |
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| BR112017028269A2 (pt) * | 2015-07-13 | 2018-09-04 | Arvinas Inc | composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto. |
| WO2017024318A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| US10772962B2 (en) * | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| MX2019005007A (es) * | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| CN106543185B (zh) * | 2016-11-10 | 2017-12-15 | 吉林大学 | 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| ES2965049T3 (es) * | 2017-07-12 | 2024-04-10 | Dana Farber Cancer Inst Inc | Compuestos para la degradación de la proteína tau |
-
2018
- 2018-07-12 ES ES18831849T patent/ES2965049T3/es active Active
- 2018-07-12 EP EP18831849.7A patent/EP3652329B1/en active Active
- 2018-07-12 WO PCT/US2018/041787 patent/WO2019014429A1/en not_active Ceased
- 2018-07-12 US US16/630,294 patent/US20210154184A1/en not_active Abandoned
- 2018-07-12 EP EP23195169.0A patent/EP4310496A3/en active Pending
- 2018-07-12 AU AU2018300982A patent/AU2018300982B2/en active Active
- 2018-07-12 CA CA3069181A patent/CA3069181A1/en active Pending
- 2018-07-12 JP JP2020501505A patent/JP7260521B2/ja active Active
-
2023
- 2023-04-06 JP JP2023062212A patent/JP2023106366A/ja not_active Withdrawn
- 2023-05-23 US US18/200,950 patent/US20240091213A1/en active Pending
-
2024
- 2024-12-02 JP JP2024209477A patent/JP2025060612A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527559A5 (https=) | ||
| JP2023106366A5 (https=) | ||
| JP2019537599A5 (https=) | ||
| ES2689029T3 (es) | Hidratos de cloruro de metiltioninio cristalinos - Parte 2 | |
| RU2009104764A (ru) | Производные пурина, как антангонисты a2a | |
| JP2016510038A5 (https=) | ||
| JP2008510828A5 (https=) | ||
| JP2009542716A5 (https=) | ||
| JP2016509047A5 (https=) | ||
| JP2012513409A5 (https=) | ||
| JP2012513410A5 (https=) | ||
| JP2010501478A5 (https=) | ||
| JP2012517428A5 (https=) | ||
| JP2018519245A5 (https=) | ||
| JP2018516238A5 (https=) | ||
| JP2016506962A5 (https=) | ||
| AR042531A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| JP2015526453A5 (https=) | ||
| JP2015532295A5 (https=) | ||
| JP2008528447A5 (https=) | ||
| JP2010524947A5 (https=) | ||
| JP2010530403A5 (https=) | ||
| JP2011506566A5 (https=) | ||
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| JP2018531987A5 (https=) |